
E25Bio Inc., a Venture Capital-backed firm, develops rapid diagnostic tests for infectious diseases.
E25Bio Inc., founded with the support of Venture Capital and grants from the NIH and Gates Foundation, focuses on developing rapid diagnostic tests for infectious diseases. The company's core mission is to provide timely and accurate diagnostics to help prevent serious complications from fever-related illnesses. E25Bio's innovative products aim to simplify the identification of infectious diseases, catering primarily to markets that require quick and reliable diagnostic solutions.
Notable affiliations include backing from prestigious investors like the Gates Foundation and NIH, which underscores the credibility and potential impact of E25Bio's technology. Key achievements include the development of rapid diagnostic tests that have the potential to revolutionize disease detection and management. Overall, E25Bio has made significant strides in enhancing public health through its cutting-edge diagnostic tools, aiming to improve healthcare outcomes globally.

Enable Biosciences

Prompt Diagnostics
prompt-dx.com

Eclipse Diagnostics

Genendeavor
genendeavor.com

ECI Biotech
ecibiotech.com

Signatur Biosciences
signatur.bio

Accelevir Diagnostics

Amplified Sciences

Biomirror Diagnostics

Burst Diagnostics
burst-dx.com

BioAnalytics

Aldatu Biosciences
aldatubio.com

Wpss.Bio
wpss.bio

Evanostics

Hera Biotech
herabiotech.com
Companies similar to E25Bio include Enable Biosciences, Prompt Diagnostics, Eclipse Diagnostics and Genendeavor.
E25Bio was founded in 2018.
E25Bio's headquarters is located in Cambridge, MA, US.
E25Bio's most recent funding round was for $5.8M (USD) in August 2020.
As of Aug 13, 2020, E25Bio has raised a total of $10.1M (USD).
E25Bio has 13 employees as of Feb 5, 2024.